Undisclosed CDH17/CEACAM5 BsADC
/ Haisco
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Preclinical development of a potential first-in-class CDH17/CEACAM5 targeted bispecific antibody drug conjugate (ADC)
(AACR 2026)
- "Abstract is embargoed at this time."
ADC • Bispecific • Late-breaking abstract • Preclinical • Oncology • CDH17 • CEACAM5
1 to 1
Of
1
Go to page
1